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Abstract: There are 4 different sialidases that have been described in humans: lysosomal (Neu1), cytoplasmic (Neu2), plasma membrane
(Neu3), and lysosomal/mitochondrial (Neu4). Previously, we have shown that Neu4 has a broad substrate specificity and is active
against glyco-conjugates, including GM2 ganglioside, at the acidic pH of 3.2. An overexpression of Neu4 in transfected neuroglia cells
from a Tay–Sachs patient shows a clearance of accumulated GM2, indicating the biological importance of Neu4. In this paper, we aimed
to characterize a minimal promoter region of the human Neu4 gene in order to understand the molecular mechanism regulating
its expression. We cloned 7 different DNA fragments from the human Neu4 promoter region into luciferase expression vectors for
a reporter assay and also performed an electrophoretic mobility shift assay to demonstrate the binding of transcription factors. We
demonstrated that –187 bp upstream of the Neu4 gene is a minimal promoter region for controlling transcription from the human
Neu4 gene. The electrophoretic mobility shift assay showed that the minimal promoter region recruits a c-myc transcription factor,
which might be responsible for regulation of Neu4 gene transcription. The data we obtained might be useful to discover small molecules,
which control selective high expression of the human Neu4 gene, resulting in the normal morphological phenotype in the lysosomes of
Tay–Sachs patients.
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1. Introduction
Sialidases (EC 3.2.1.18), also known as neuraminidases, are
glycohydrolytic enzymes responsible for removing sialic
acid residue from sialylated glycoproteins, glycolipids,
and oligosaccharides (Saito and Yu, 1995). Sialidases have
a wide distribution in nature among viruses, bacteria,
protozoa, and vertebrates (Svennerholm, 1963; Saito
and Yu, 1995). So far, 4 types of sialidases have been
identified in humans and characterized according to their
subcellular distribution, substrate specificity, and stability.
These sialidases are lysosomal Neu1, cytosolic Neu2,
plasma membrane Neu3, and lysosomal/mitochondrial
membrane Neu4 (Seyrantepe et al., 2004).
The sialidase Neu4 enzyme is expressed by the gene
NEU4 (NCBI Gene ID: 129807), which maps in the
telomeric region of the long arm of the human chromosome
2 (2q37). The NEU4 gene was discovered as a result of a
sequence database search that revealed homology to the
human cytosolic sialidase NEU2 gene (Monti et al., 2004).
The sialidase Neu4 enzyme has the highest expression
level in the liver and it is also ubiquitously expressed in
all central nervous system districts, the colon, the small
intestine, the kidney, the heart, skeletal muscle, and
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the placenta. Targeting of the sialidase Neu4 enzyme to
lysosomes by the mannose 6-phospate receptor has been
shown (Seyrantepe et al., 2004). It has also been shown
that the sialidase Neu4 enzyme localizes in the lysosomal
lumen as a soluble hydrolase. The sialidase Neu4 enzyme
has 2 major isoforms: a short form containing 484 amino
acids and a long form containing 496 amino acids. It has
been suggested that the long form localizes in mitochondria
and the short form is associated with the endoplasmic
reticulum (Bigi et al., 2010). Seyrantepe et al. (2004) first
biochemically characterized the Neu4 enzyme, which
has an almost equal broad substrate specificity against
glycoproteins (mucin), oligosaccharides (sialyllactose)
and sialylated glycolipids (mixed bovine gangliosides), and
synthetic substrates 2’-(4-methylumbelliferyl)-alpha-DN-acetylneuraminic acid (4-MU-NANA or 4MU-NeuAc)
at an acidic pH of 3.2 (Monti et al., 2004; Seyrantepe et
al., 2004). Overexpression of the sialidase Neu4 enzyme
in sialidase Neu1-deficient sialidosis fibroblasts has been
associated with the clearance of accumulated substrates
and normal morphological phenotype of the lysosomal
compartment. In addition, the complete elimination of
storage materials in sialidosis and of galactosialidosis
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cells was achieved by only 3–5% of Neu4-expressing cells,
indicating the therapeutic potential of the sialidase Neu4
enzyme in sialidosis and galactosialidosis for enzyme
replacement therapy (Seyrantepe et al., 2004). Sialidase
Neu4-deficient (Neu4–/–) mice showed vacuolization and
lysosomal storage in lung and spleen cells. Neu4–/– mice
also have increased levels of GD1a ganglioside and decreased
levels of GM1 ganglioside in the brain, which supports the
evidence for sialidase Neu4 enzyme desialylation activity
against brain gangliosides (Seyrantepe et al., 2008). It has
been shown that Neu4 is downregulated in human colon
cancer cells and that the overexpression of Neu4 in cultured
cells accelerates apoptosis and decreases invasiveness and
motility (Miyagi, 2008).
Tay–Sachs disease, which is due to a deficiency of the
β-hexosaminidase A enzyme, causes an accumulation of GM2
ganglioside in lysosomes resulting in neurodegeneration
(Kolodny, 1966). Mouse models of Tay–Sachs disease have
been generated by targeted disruption of the HexA gene.
Analysis of these knockout mice revealed that although
GM2 ganglioside accumulated in the brain, the mice did
not present any kind of human Tay–Sachs phenotypelike behavioral or motor abnormalities for at least 1 year.
It has been suggested that sialidase(s) in HexA-deficient
(HexA–/–) mice can convert GM2 to GA2 ganglioside, which
is an asialo-GM2 form, and then to lactocyl ceramide by
the HexB isoenzyme (Cohen-Tannoudji et al., 1995; Sango
et al. 1995; Phaneuf et al., 1996). This metabolic bypass
prevents mice from presenting an early phenotype of
Tay–Sachs disease. However, we previously showed that
mice deficient in both HexA and Neu4 exhibit epileptic
crises, degenerating neurons, motor impairment-like
tremors, weakness, and spasticity. In addition, elevated
GM2 ganglioside accumulation has been observed in
comparison to single knockout HexA–/– or Neu4–/– mice
(Seyrantepe et al., 2010). The data revealed that due to
a sialidase Neu4 enzyme deficiency HexA–/– mice show
a severe phenotype supporting the modifier role of the
sialidase Neu4 enzyme in metabolic bypass in this Tay–
Sachs disease mouse model. All these data indicate that the
sialidase Neu4 enzyme might be a potential therapeutic
modifier by a selective pharmacologic induction through
its upregulation with small molecules (Seyrantepe et al.,
2008, 2010).
In this work, we aimed to characterize the promoter
region of the human sialidase NEU4 gene, which has not
yet been reported. We also showed specific interactions of
transcription factor c-myc in the promoter region, which
has the potential to be a regulator of Neu 4 gene expression.

2. Materials and methods
2.1. Bioinformatics
The –3000 bp upstream region from the human NEU4
gene start codon (ATG) was considered to be a region
containing the regulatory elements for the Neu4 gene. The
sequence of –3000 bp was analyzed using the Transcription
Element Search System (TESS) tool for the mapping of
transcription binding sites.
2.2. Plasmid construction
Seven
pairs
of
primers
(F1:5’GGTACCCTCCTGGGTGCCCATCTG-3’,
F2:5’GGTAC
CTCTCTGGAGCAGCAGACC-3’,
F3:5’G G TA C C G T G A AT G G G A C T G G C A G G A G - 3 ’,
F4:5’-GGTACCGGGGGAAGCTTTCCTTAACC-3’,
F5:5’-GGTACCACACCCTGGCCAG
ACAGC-3,
F6:5’-GGTACCCCTGTCCCTGAGCGGAAC-3’, F7:5’GGTACCCTCCGTGT CAGTGTGCATTC- 3’, Reverse
primer: 5’- GCTAGCGCTGCAGAGCTCATCATGG- 3’)
were designed to obtain overlapping DNA fragments 187
bp, 358 bp, 591 bp, 1198 bp, 1592 bp, 2364 bp, and 3000 bp
in length. Human genomic DNA was amplified by PCR
with i-Taq DNA Polymerase (Intron Biotechnology) and
cloned into the pCR 2.1 TOPO vector using the TOPO TA
Cloning Kit (Invitrogen) according to the manufacturer’s
instructions. Seven different fragments were subcloned
into the pGL 4.12 (Firefly) plasmid with NheI and KpnI
restriction sites from the pCR 2.1 TOPO vector using T4
DNA Ligase (Invitrogen).
2.3. Cell culture, transient transfection, and luciferase
assay
HeLa cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% FBS (heat-inactivated),
1% penicillin/streptomycin, and 2 mM L-glutamine in a
humidified incubator at 37 °C under 5% CO2. HeLa cells
were inoculated in 96-well plates at a density of 1 × 104
cells/well to provide 90% confluency prior to transfection
before 24 h. Turbofect in vitro transfection reagent
(Fermentas) was used according to the manufacturer’s
instructions for all of the transfections. All reporter
assays were performed 3 times and included cells without
transfection as blanks. The cells were also co-transfected
with both a promoter-less empty pGL 4.12 vector and
a pGL 4.74 vector as a negative control. The luciferase
assay was optimized using different amounts of DNA
molecules and different incubation times. According to
optimization assays, the cells were co-transfected with 210
ng of pGL 4.12 (Promega), which contained 7 different
DNA fragments as a promoter construct and 7 ng of pGL
4.74 (Promega), which expresses renilla luciferase as an
internal control for transfection efficiency using Turbofect
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transfection reagent (Fermentas) without serum. After
transfection, the cells were incubated at 37 °C under
5% CO2 for 4 h, then replaced with fresh medium, and
incubated for 24 h for the reporter assay. The cells were
washed with PBS (phosphate buffer saline) and lysed with
20 μL of 1X Passive Lysis Buffer (Promega) by shaking
for 15 min on an orbital shaker. After the cells were
lysed, luciferase activities were measured with a platereading luminometer (Thermo, VarioSkan) using a Dual
Luciferase Reporter Assay System kit (Promega) according
to the manufacturer’s instructions by injecting 100 μL of
both Dual Luciferase Reporter Assay System reagents into
20 μL of cell lysate. Luciferase activities were calculated
as a ratio of pGL 4.12 to pGL 4.74, revealing a promoter
activity relative to pGL 4.12 basic.
2.4. Nuclear extract preparation and electrophoretic
mobility shift assay
Nuclear proteins were isolated from HeLa cells using
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Scientific). Concentrations of the isolated
proteins were determined using a Pierce BCA Protein
Assay Kit (Thermo Scientific). Fragments were amplified
from the 5’ upstream region of the NEU4 gene to
produce double stranded probes with biotin. A Biotin 3’
End DNA Labeling Kit (Thermo Scientific) was used to
biotinylate 5 pmol of the 3’ ends of the F1 fragment (187
bp), F2 fragment (358 bp), and F3 fragment (591 bp). An
electrophoretic mobility shift assay (EMSA) was performed
using a LightShift Chemiluminescent EMSA Kit (Thermo
Scientific). Binding reactions included 1X binding buffer
supplied with the kit, 5 µg of nuclear extract, 5 pmol of
biotin-labeled DNA fragments, and 50 ng/μL of salmon
sperm, followed by incubation at room temperature for 20
min. For competition assays, binding reactions included
1X binding buffer supplied with the kit, 5 µg of nuclear
extract, and a 50-fold excess of unlabeled DNA fragments
(F1, F2, F3 fragments for relative reactions) as competitor.
These were pre-incubated for 5 min at room temperature,
then 5 pmol of biotinylated DNA fragments was added and
incubated for an additional 20 min at room temperature to
demonstrate the specificity of DNA–protein interactions.
For the supershift assay, 2.5 µg of an antibody (Sigma)
directed against the transcription factor c-myc was
incubated with nuclear extract on ice for 1 h, then added
into the binding reaction prior to the addition of the biotinlabeled DNA. Protein–DNA complexes were separated on
3.5% native polyacrylamide gel electrophoresis in 0.5X
Tris-Borate-EDTA buffer for 1 h and then transferred to a
positively charged nylon membrane (HyBond-N+) in 0.5X
Tris-Borate-EDTA buffer for 1 h. Protein–DNA complexes
were cross-linked to the membrane at 120 mJ/cm2 of UV
light and detected using the Chemiluminescent Nucleic
Acid Detection Module (Thermo Scientific).
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3. Results
Sequence analysis of the –3000 bp upstream region of
the human Neu4 gene using the TESS tool revealed that
the Neu4 promoter harbored several transcription factor
binding sites (C/EBP, CREB, AP-1, c-myc,c-myb, SP-1,
cEtc-2, YY1, and MyoD) and the absence of a TATA box.
In addition, the analysis of GC boxes using Molecular
Biology Core Facilities (MBCF) Oligo Calculator revealed
that the region –3000 bp upstream of human Neu4 has
61% GC content (Figures 1A and 1B).
The promoter activity of the human Neu4 gene was
studied by transient transfection in HeLa cells. In order
to characterize the upstream regulators, we used a dual
luciferase reporter system because of its experimental
accuracy and high sensitivity (as low as femtograms of
luciferase). Amplified DNA fragments were subcloned into
a pGL 4.12 vector. We confirmed that there was no DNA
polymerase error in the insert by sequencing (data not
shown). We also optimized the assay parameters and found
that the ratio of 30:1 (pGL 4.12:pGL 4.74) was optimal for
the Dual Luciferase Reporter System. All reporter assays
were repeated 3 times. Luciferase activities are shown
as a relative fold activity change to promoter-less pGL
4.12 vector. The region located on –187 bp (F1) showed
minimal promoter activity and high luciferase expression,
indicating the importance of potential regulatory elements
such as c-myc (Figure 1C).
The reporters containing the –187 bp (F1), –358
bp (F2), –591 bp (F3), and –1187 bp (F4) fragments of
sequence all exhibited similar, high levels of luciferase
expression. Therefore, in order to examine the association
of transcription factors with putative binding sites in the
promoter region, we used only the –187 bp (F1), –358 bp
(F2), and –591 bp (F3) fragments as probes for EMSA. We
showed the presence of transcription factor binding site(s)
by shift formation, as illustrated in Figure 2. Specific shift
formation was only detected for the F1 fragment (A) and
to some extent for F2 (B). This is due to the fact that we
had difficulty obtaining well resolved results for F3 (C) in
the competition assays, most likely because the competitor
we used successfully degraded the F3 shift and reduced
the intensity. Therefore, specific transcriptional factor
bindings to the F3 fragment, when combined with the
competitor, were disrupted and the F3-protein complex
degraded.
To determine the interaction of transcription factor
c-myc with its binding site, which is located –114 bp from
the start codon (ATG) and has the sequence of CACCGT,
we performed a supershift assay using the anti c-myc
antibody. As shown in Figure 3, we found that c-myc
specifically bound to the –187 bp upstream region.
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Figure 1. A DNA sequence analysis of the Neu4 promoter showing high score transcription binding
site predictions (A). Sequence analyses were performed using TESS algorithms. Potential transcription
factor binding sites are underlined (B). Luciferase assays of deleted fragments were performed in
triplicate (C). Each value is expressed as mean ± standard deviations. Fisher’s least squared significant
difference test was performed for post-hoc analysis following ANOVA. Statistical significance was
determined as *P < 0.05 compared to the control.
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Figure 2. An image showing the EMSA results of the (A) –187 bp upstream region (F1), (B)
–358 bp upstream region (F2) and (C) –591 bp upstream region (F3). Lane 1: free biotin labeled
probes without nuclear extract; lane 2: labeled probes with 5 µg of nuclear extract; lane 3: labeled
probes with nuclear extract and 50-fold excess of unlabeled probe for competition assay.

4. Discussion
Sialidases (neuraminidases) are glycohydrolytic enzymes
that remove sialic acid residues from glycoconjugates
(Saito and Yu, 1995). They show a wide distribution in
nature, from viruses to vertebrates. In humans, 4 types of
sialidases have been identified and cloned so far. It has been
shown that lysosomal/mitochondrial sialidase 4 (Neu4) has
activity against sialylated glycoproteins, oligosaccharides,
and glycolipids in vitro. In Neu4 transfected Tay–Sachs
neuroglia cells, clearance of accumulated GM2 ganglioside
has been shown (Seyrantepe et al., 2004). Neu4 deficient
mice also show an increased GD1a and a decrease in GM1
ganglioside levels in the brain, indicating the activity of
Neu4 against gangliosides in vivo (Seyrantepe et al., 2008).
In this study, our aim was to characterize the 5’
upstream regulatory region of the human Neu4 sialidase
gene. Although the biochemical properties of the human
sialidase Neu4 enzyme have previously been reported, the
Neu4 promoter region has not been characterized yet.
Our data provided an important clue about the molecular
mechanism regulating human Neu4 gene expression. We
focused on the –3000 bp upstream region of the human
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Neu4 gene as a candidate promoter region. Bioinformatic
analysis using TESS tool revealed several putative
transcription factor binding sites such as c-myc, CREB,
SP-1, YY1, and AP-1 in the TATA-less promoter. The data
obtained using the Dual Luciferase Reporter System showed,
by demonstrating the highest luminescence among all the
bp fragment regions, that the –187 bp upstream region (F1
fragment) has minimal transcriptional regulatory activity
for the human Neu4 gene. We found that the fold activity
change of luminescence gradually decreased between the
–187 bp and –1187 bp region. On the other hand, the –358
bp upstream region showed a significant decrease in fold
activities due to potential elements probably responsible
for the downregulation of Neu4 gene. In addition,
significantly decreased fold activities of luminescence
were detected in the –1592 bp, –2364 bp, and –3000 bp
upstream regions due to the effect of potential silencer
elements. The –187 bp region (F1 fragment) has dominant
promoter activity by showing 6 times higher fold activity
than the –1592 bp region (F5 fragment). EMSA revealed
that the –187 bp, –358 bp, and –591 bp upstream regions
recruited some transcription factors as seen in “shift”
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Figure 3. An image showing the result of the –187 bp upstream
region (F1) with c-myc supershift. Lane 1: free biotin labeled
probes without nuclear extract; lane 2: labeled probes with 5 µg
of nuclear extract; lane 3: labeled probes with nuclear extract and
2.5 µg of antibody (Sigma) against transcription factor c-myc for
supershift assay; lane 4: labeled probes with nuclear extract and
50-fold excess of unlabeled probe for competition assay.

formation with the incubation of biotinlated DNA and
nuclear proteins isolated from HeLa cells. The addition
of the unlabeled 187 bp, 358 bp, and 591 bp fragments
as competitors into relative binding reactions proved the
specificity of the binding of transcription factors to the
candidate promoter region. EMSA also confirmed further
supporting evidence for the regulatory role of the –187
bp upstream region (F1 fragment), as we determined the

formation of a “specific shift” at the protein level, besides
its highest luminescence fold activity. In particular, we
showed the binding of transcription factor c-myc to our
minimal promoter region by supershift assay. The highest
luminescence obtained from the –187 bp upstream region
(F1 fragment) of the human Neu4 gene may be a result of
the predicted transcription factor binding sites for c-myc,
which are also responsible for transcriptional upregulation
of many genes involved in cellular events such as cell
proliferation and differentiation.
In the future, the data we presented in this paper can
be used to discover small molecules that may regulate
human Neu4 gene expression. Selective high expression
or silencing of the Neu4 gene might be achieved by
using drugs or small molecules. High expression of the
Neu4 gene and increased levels of sialidase Neu4 enzyme
activity in tissues can clear accumulated GM2 ganglioside
in the lysosomes of Tay–Sachs patients caused by
β-hexosaminidase A deficiency.
It has been shown that Neu4 is downregulated in
human colon cancer cells and that the overexpression of
Neu4 in cultured cells accelerates apoptosis and decreases
invasiveness and motility. Research directed at studying
the upregulation of human Neu4 gene expression by
selective binding of c-myc to the promoter region might
be also important to treat human colon cancer. Finally, the
importance of up and/or downregulation of Neu4 gene
expression in the degradation of biomolecules, cellular
communication, cell growth and differentiation, and cell
death would be clarified.
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